13F-HR filed by VHCP Management III, LLC
VHCP Management III, LLC filed this 13F-HR for the quarter ended 2019-12-31, filed 2020-02-13, with 18 holding rows worth $503,631,000.
- Accession
- 0000950123-20-001882
- Filer
- CIK 1738053
- Filed
- 2020-02-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2019
A holdings report, 18 entries on the cover page, a total value of $503,631,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $503,631,000 with VALUE read as thousands by filing date, 13F file number 028-18930. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AXSOME THERAPEUTICS INC. COM | 05464T104 | Stock | 1,547,994 | $160,001,000 | thousands by filing date | |
| CONSTELLATION PHARMACEUTICALS INC. | 210373106 | Common Stock | 2,516,242 | $118,540,000 | thousands by filing date | |
| Milestone Pharmaceuticals Inc | 59935V107 | COM | 2,066,529 | $33,085,000 | thousands by filing date | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 767,938 | $29,950,000 | thousands by filing date | |
| 89BIO INC | 282559103 | COM | 958,765 | $25,206,000 | thousands by filing date | |
| 10X GENOMICS INC CL A COM | 88025U109 | Stock | 300,000 | $22,875,000 | thousands by filing date | |
| FORTY SEVEN INC | 34983P104 | COM | 516,381 | $20,330,000 | thousands by filing date | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 575,000 | $19,728,000 | thousands by filing date | |
| IVERIC BIO INC | 46583P102 | COM | 1,699,797 | $14,584,000 | thousands by filing date | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 619,905 | $11,041,000 | thousands by filing date | |
| Adverum Biotechnologies, Inc. | 00773U108 | Common Stock | 946,234 | $10,901,000 | thousands by filing date | |
| MARINUS PHARMACEUTICALS INC | 56854Q101 | COM | 5,016,164 | $10,835,000 | thousands by filing date | |
| Mersana Therapeutics Inc | 59045L106 | Common Stock | 1,561,389 | $8,947,000 | thousands by filing date | |
| MYOVANT SCIENCES LTD | G637AM102 | COMMON STOCK-FO | 455,255 | $7,066,000 | thousands by filing date | |
| NEXTCURE INC | 65343E108 | COM | 119,693 | $6,742,000 | thousands by filing date | |
| ObsEva SA | H5861P103 | COM | 810,264 | $3,095,000 | thousands by filing date | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 80,929 | $571,000 | thousands by filing date | |
| BELLEROPHON THERAPEUTICS INC | 078771102 | COM | 383,955 | $134,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-20-001882 | this filing | 2020-02-13 | acceptance time not in the bulk data set |